Is NCT06419205 recruiting in Hollywood, FL?

Yes, NCT06419205 is currently recruiting participants at its Hollywood, FL location. This iga nephropathy clinical trial is actively enrolling qualified participants.

How do I join the iga nephropathy clinical trial in Hollywood?

To join this clinical trial in Hollywood, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Hollywood clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

IgA Nephropathy Clinical Trial in Hollywood, FL

About This IgA Nephropathy Study in Hollywood

A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)

Sponsor: Akebia Therapeutics

Who Can Participate

Inclusion Criteria

All participants

Male or female participants aged ≥16 years.

uPCR ≥0.5 g/g (from the average of 3 first morning voids \[FMVs\]).

Screening eGFR ≥30 mL/min/1.73m2 calculated by the Chronic Kidney Disease Epidemiology Collaboration creatinine equation (CKD-EPI GFR).

Participants receiving a renin-angiotensin-aldosterone system (RAAS) inhibitor, sodium-glucose cotransporter-2 (SGLT2) inhibitor, sparsentan, or atrasenten must have been on a stable dose (at the maximum recommended dose according to local guidelines or maximum tolerated dose) for at least 8 weeks prior to Study Day 1 and the dose is projected to remain stable until completion of the study. Participants with IgAN only

Kidney biopsy-proven diagnosis of IgAN with a kidney biopsy that is obtained within 10 years of Day 1 or within 5 years of Day 1 if the participant is known or suspected of also having diabetic nephropathy. Participants with LN only

Clinical diagnosis of systemic lupus erythematosus (SLE)

Kidney biopsy-proven diagnosis of LN with a kidney biopsy that is obtained within 24 weeks of Day 1.

Diagnosis of active focal or diffuse LN class III or IV Participants with C3G only

Kidney biopsy-proven diagnosis of C3G, either dense deposit disease (DDD) or complement component 3 glomerulonephritis (C3GN), with a kidney biopsy that is obtained within 52 weeks of Day 1.

Participants receiving mycophenolate mofetil (MMF) (or mycophenolic acid) or prednisone ≥10 mg/d or equivalent must have been on a stable dose for at least 12 weeks before Day 1 that is projected to remain stable until completion of the study. Key

Exclusion Criteria

All participants

Rapidly progressive glomerulonephritis defined as a 50% decline in eGFR within 12 weeks of screening.

Concomitant significant renal disease other than IgAN, C3G, or LN per investigator discretion.

Participants with a history of and/or presence of anti-factor H antibodies at screening.

Uncontrolled hypertension with mean seated systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg based on the average of 2 measurements obtained at approximately 2-minute intervals after the individual has been sitting for 5 minutes.

Kidney, other solid organs, or bone marrow transplantation prior to or expected to occur during the study.

History of splenectomy. Participants with IgAN only

Secondary forms of IgAN

Received systemic corticosteroid therapy, oral budenoside, or any other form of immunosuppressive therapy within 12 weeks before Day 1. Participants with LN only

Lymphocyte count below 0.5 × 109/L at screening.

Received any of Cyclophosphamide, Calcineurin inhibitors, IV methylprednisolone, IV immunoglobulin therapy, Belimumab, Obinutuzumab and Rituximab treatments at protocol specified time points. Participants with C3G only

Evidence of monoclonal gammopathy of unclear significance, infections, malignancy, autoimmune diseases, or other conditions to which C3G is secondary.

Received systemic corticosteroid therapy, eculizumab, iptacopan, pegcetacoplan, or any other form of immunosuppressive therapy ≤12 weeks before Day 1, except for MMF (or mycophenolic acid), which is permitted.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Hollywood?

Yes, this clinical trial (NCT06419205) has an active research site in Hollywood, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

IgA Nephropathy Treatment Options in Hollywood, FL

If you're searching for iga nephropathy treatment options in Hollywood, FL, this clinical trial (NCT06419205) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Hollywood research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced iga nephropathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all iga nephropathy clinical trials near you to find additional studies recruiting in your area.

IgA Nephropathy Clinical Trial in Hollywood, FL

Expert Care in Hollywood

IRB Approved

No-Cost Care

Apply for This Hollywood Location

Why Participate?

Simple Process